Call to Action

Berlin, 28 April 2017

This Call to Action strongly urges the G20 to commit investment in research, innovation and development of innovative health technologies to counter threats posed by Antimicrobial Resistance (AMR), Poverty-Related and Neglected Diseases (PRNDs) and pandemics.

We call on the G20 to agree to take the following actions:

  1. Provide political support to address the inter-related issues of AMR, pandemic preparedness/ response and PRNDs
  • Include a commitment to research and development (R&D) of products and interventions for global health in the outcome document of the Meeting of the G20 Ministers of Health, in the G20 Communiqué and in all relevant G20 agendas, with a focus on addressing the threat of a broad spectrum of emerging antimicrobial resistance from a variety of bacteria, parasites, viruses and fungi, as well as emerging infectious diseases.
  1. Increase financial support and its co-ordination across the G20 and partner countries to ensure sustainable, long-term funding for global health innovation, with a focus on AMR, pandemic preparedness/ response and PRNDs.
  • Coordinate funding between G20 countries to ensure inefficiencies and duplication of efforts are avoided, and that the significant costs of product development are shared among nations.
  1. Encourage business, philanthropic organizations and other financing institutions from the G20 to increase investment in global health innovation, in the interrelated areas of AMR, pandemic preparedness / response and PRNDs.
  • Promote financial support to the work of multinational partnership mechanisms such as Product Development Partnerships (PDPs) and other public-private collaborations to expand global health innovation. 
  1. Mobilize G20 public health and scientific expertise to address antimicrobial resistance (AMR) in both neglected and major poverty diseases by:
  • Supporting global efforts to develop new tools, interventions and approaches to address AMR.
  • Assisting low and middle-income G20 partner countries in building up their research and product development capacity for the fight against AMR.
  • Promoting open data sharing in R&D to help technology transfers and strengthening of research capacity in G20 and partner countries to address AMR.

We invite all those who share this vision to sign and support this Call to Action

In advance of the 2017 Hamburg Summit we would like to commend G20 leaders, and especially the German Presidency, for putting the 2030 Agenda for Sustainable Development and global health at the top of the G20 agenda. We represent a group of like-minded advocates and experts from public and private sector organizations calling on the G20 to commit political and financial resources as well as expertise to science, technology and innovation (STI) in global health.

We support the view of Chancellor Merkel that “health is an issue that belongs on the G20 agenda” and her belief that addressing the world’s health challenges should become a permanent agenda item. Medical innovation and the policy changes needed to transform global health take years to develop and take effect, and require long-term political and economic commitment.[1]

Antimicrobial Resistance (AMR)

Growing antimicrobial resistance (AMR) by a variety of pathogens including bacteria, parasites, viruses and fungi is an increasingly serious threat to economic development and global public health, and requires urgent and coordinated action from governments, the private sector, academia, and civil society. Although the world is broadly on track to achieving the target of less than 3% of people living in extreme poverty by 2030, the World Bank has recently found that AMR is putting this target out of reach.2

Pandemic preparedness/ response

The Ebola outbreak in West Africa and the recent outbreak of the Zika virus in the Americas underscored the fact that the world remains woefully underprepared for pandemics. The Ebola epidemic in western Africa accounted for more than 11.000 deaths and cost Guinea, Sierra Leone, and Liberia an estimated US$2.2 billion in lost economic output.3

Poverty-Related and Neglected Diseases (PRNDs)

HIV/AIDS, TB, Malaria, and other diseases such as pneumonia and typhoid still cause high levels of mortality and morbidity across the globe, including in several G20 countries.4 These are diseases of poverty, with 94.8% of cases found in low-income countries and among poor and marginalised populations in middle-income countries. They also fuel the cycle of poverty, exacting a heavy economic toll on affected families, which imposes a significant ‘growth penalty’ on entire regions.

Looking ahead, the risk of resistance and emerging infectious diseases, combined with increased transnational mobility, poses a major challenge for the global health community. Innovative technologies for the protection of new vulnerable groups, such as migrant populations, are essential components of control, elimination and eradication strategies moving forward.

The World Bank has estimated that by 2050, these issues will push an additional 28.3 million people into poverty, increase global healthcare costs by $1.2 trillion and cause low income countries to lose more than 5% GDP. G20 leadership in combatting neglected diseases could lead to significant reductions in the global disease burden, lifting millions out of poverty and averting billions of dollars of economic and social costs.

________________________________________________________________________________________________________

[1] B20 Health Initiative Policy Paper Stepping Up Global Health: Towards Resilient, Responsible, and Responsive Health Systems
[2] World Bank Group, ‘Drug resistant infections: A Threat to Our Economic Future’, accessed 20 April 2017, http://pubdocs.worldbank.org/en/527731474225046104/AMR-Discussion-Draft-Sept18updated.pdf
[3] Ebola Response Fact Sheet’ (April 6, 2016), accessed February 8, 2017, http://www.worldbank.org/en/topic/health/brief/world-bank-group-ebola-fact-sheet
[4] World Bank Group, ‘Drug resistant infections: A Threat to Our Economic Future’, accessed 20 April 2017, http://pubdocs.worldbank.org/en/527731474225046104/AMR-Discussion-Draft-Sept18updated.pdf

Sign the Call to Action

Signatories (112)
  • Mr. MdB Stephan Albani – Member of the Bundestag and Chair of the European TB Caucus
  • Ms. MdB Kordula Schulz-Asche – Member of the Bundestag
  • Dr. Richard Hatchett – CEO, Coalition for Epidemic Preparedness Innovations (CEPI)
  • Dr. Peter Jackson – Founding Member & Executive Chairman AMR Centre, CARB-X
  • Ms. Jamie Bay Nishi – Director, the Global Health Technologies Coalition (GHTC)
  • Mr. Alan Donnelly – Executive Chairman, Sovereign Strategy
  • Dr. Kei Katsuno – Director, Global Health Innovative Technology (GHIT)
  • Ms. Claudia Diebold – Executive Officer, UNITAID
  • Ms. Sanne Fournier-Wendes – Advisor to the Executive Director, UNITAID
  • Ms. Tara Hayward – Vice President, Sabin Vaccine Institute
  • Ms. Claire Wingfield – Senior Product Development Policy Officer,  PATH
  • Ms. Silvia Ferazzi – External Relations Officer, Medicines for Malaria Venture (MMV)
  • Mr. Ben Alsdurf – External Relations Manager, TB Alliance
  • Dr. Abdullah Aldahmash – Director of Prince Naif Health Research Center, King Saud University
  • Ms. Katharina Kuss – Project Manager, Spanish Foundation for International Cooperation, Health and Social Affairs (FCSAI)
  • Mr. Jerome St-Denis – Senior Advocacy and Resource Mobilization Officer, Foundation for Innovative New Diagnostics  (FIND)
  • Ms. Alix Beith – AMR Consultant, World Health Organisation (WHO)
  • Mr. Henry Lishi Li – Head of Economic, Social and Political Research at Antimicrobial Resistance Centre, London School of Hygiene & Tropical Medicine
  • Ms. Chaoyi Chen – Director of Fundraising and Development, Fudan University Education Development Foundation
  • Ms. Ya Gao – Healthcare Data Analyst, Partners HealthCare
  • Ms. Gursharon Mangat – Principal and Owner, Inspired Marketing Associates
  • Fritzie Dizon – Director for Gift Planning, Columbia University
  • Van Furniss – Development Officer, Columbia University
  • Dr. Ajay Mistry – Oppilotech Ltd.
  • Dr. Roger Harrison – Senior Lecturer, University of Manchester
  • Ms. Van Furniss – Development Officer, Columbia University
  • Ms. Fritzie Dizon – Director for Gift Planning, Columbia University
  • Professor Abdullah M. Aldamash – Prince Naif Bin AbdulAziz Health Research Cener
  • Mr. Alberto Colorado – Coordinator, Americas TB Coalition
  • Ms. Laura Hoemeke – Director of Communications and Advocacy, IntraHealth International
  • Ms. Erin Will Morton – Director of External Affairs, TB Alliance
  • Ms. Dara Erck – Vice President External Affairs, Aeras
  • Ms. Rabita Aziz – Policy Resech Coordinator, Infectious Diesases Society of America
  • Ms. Jaclyn Levy – Program Officer for Science and Research Policy, IDSA
  • Professor Carlos del Rio – Professor of Global Health, Rollins School of Public Health of Emory University
  • Dr. Richard Murphy – Assistant Professor at the Division of Infectious Diseases, UCLA
  • Professor Kenneth Mayer – Professor at Harvard Medical School and Medical Research Director at Fenway Health
  • Mr. Joshua Barocas, MD – Managing Director, Massachusetts General Hospital; Harvard Medical School
  • Ms. Marcia Goldberg, MD – Professor, Massachusetts General Hospital; Harvard Medical School
  • Ms. Karen Manning – Medical Secretary, Massachusetts General Hospital; Harvard Medical School
  • Ms. Jenny Blair – Policy Officer, PATH
  • Ms. Taylor Capizola – Program Assistant, GHTC
  • Ms. Alyssa R. Letourneau, MD, MPH – Director, MGH Antimicrobial Stewardship Program at Harvard Medical School
  • Dr. Ana Weil – Physician Scientist,  Massachusetts General Hospital; Harvard Medical School
  • Ms. Ingrid Bassett – Associate Professor of Medicine, Massachusetts General Hospital, Harvard Medical School
  • Professor Barbara Van Der Pol, PhD, MPH – Associate Professor of Medicine, University of Alabama at Birmingham
  • Ms. KC Coffey, M.D – Infectious Diseases Fellow, Massachusetts General Hospital; Harvard Medical School
  • Ramnath Subbaraman, MD – Associate Physician, Brigham and Women’s Hospital; Harvard Medical School
  • Ms. Caitlin Dugdale, MD – Massachusetts General Hospital
  • DR. Bamal’empyulo Augustin Karumba – Medical Doctor, United Nations Volunteers and United Nations Mission in Liberia
  • Ms. Christine Lubinski – Vice-President for Global Health, Infectious Diseases Society of America
  • Dr. Rangarajan Sampath – Senior Director for R&D, Ibis Biosciences/Abbott
  • Ms Carmen Contreras – Director of Intervention Projects, Socios En Salud
  • Mr. Nimer Ortuño-Gutiérrez – Medical Advisor, The Damien Foundation
  • Mr. Paul Jensen – Director of Policy and Strategy, International Union Against Tuberculosis and Lung Disease
  • Mr. Luckyboy Edison Mkhondwane – National Training Coordinator, Treatment Action Campaign
  • Mr. Sizwe Nombasa Gxuluwe – Programme Officer, WACI Health
  • Mr. Isbat Rifat – Senior Sector Specialist, Knowledge Management, TB Control Programme, BRAC
  • Ms. Jahnabi Goswami – Assam Network of Positive People
  • Mr. Muluken Melese – Heal TB Project Director, Management Sciences for Health
  • Ms. Jessica Snowden
  • Ms. Patricia Bond
  • Dr. Maurice Bolo – Director, The Scinnovent Centre
  • Mr. James Kamau – CEO, KETAM
  • Mrs. Maryam Rumaney – Senior Researcher, Stellenbosch University
  • Ms. Belinda Ostrowsky, MD, MPH – Health System Director of Epidemiology, Antimicrobial Stewardship, & Infection Prevention, Montefiore Medical cCnter & Albert Einstein College of Medicine
  • Mr. Henry F. Chambers – Professor of Medicine, University of California San Francisco
  • Ms. Helen Boucher, MD – Professor of Medicine, Tufts Medical Center and Tufts University School of Medicine
  • Dr. Frank Cobelens – Professor of Global Health and Chair Executive Board, Amsterdam Institute for Global Health and Development
  • Ms. Colleen Nash MD, MPH – Rush University Medical Center
  • Ms. Danielle Heiberg – Senior Advocacy Manager, Global Health Council
  • Mr. Ronald Kempers – CEO, Mymetics Corporation
  • Mr. Jackson Eby, Ph.D. – Senior Scientist, Vedantra Pharmaceuticals
  • Mr. Zachary Willis – Assistant Professor of Pediatrics, University of North Carolina at Chapel Hill
  • Professor Peter Horby- Professor of Emerging Infectious Diseases, University of Oxford
  • Mr. Gabriel Rebollon – President, Fundación Sangre Panama
  • Mr. Sten Vermund – Dean, Yale School of Public Health
  • Ms. Amélie Poojary – Development and Communications Manager, The NVLD Project
  • Dr. Francis Ohanyido – Chair, Board of Directors/President, West African Academy of Public Health (WAAPH)
  • Mr. Ariel Blocker – Reader in Microbiology, University of Bristol
  • Dr. Ritu Banerjee – Associate Professor, Pediatric Infectious Diseases, Vanderbilt University Medical Center
  • Mr. Matthew Kronman – Dr. Associate Professor of Pediatric Infectious Diseases, University of Washington
  • Ms. Colleen Nash – MD, MPH; Rush University Medical Center
  • Dr. Frank Cobelens – Professor of Global Health; Chair Executive Board , Amsterdam Institute for Global Health and Development
  • Ms. Danielle Heiberg – Senior Advocacy Manager, Global Health Council
  • Mr. Ronald Kempers – CEO, Mymetics Corporation
  • Mr. Tomas Lopez – Peña Ordoñez – Head of Area Global Health Reserch for Development , National Helth Research Institute Carlos III
  • Ms. Maria J. Garcia – Tenured Lecturer, Autonoma University of Madrid
  • Ms. Molly Hayes – Clinical Pharmacist and Antimicrobial Stewardship, The Children’s Hospital of Philadelphia
  • Mr. Jen Lighter – Hospital Epidemiologist, NYU Langone Medical Center
  • Ms. Sunanda Gaur – Rutgers University
  • Dr.  Eusebio Gainza – R&D Manager, Biopraxis
  • Mr. David A. Rosen – Instructor in Pediatric Infectious Diseases, Washington University
  • Ms. Christina Gagliardo M.D – Pediatric Infectious Disease Physician
  • Ms. Erin McCreary – Infectious Diseases Pharmacist, University of Wisconsin Health
  • Ms. Michelle Crawford –  Infectious Diseases/Antimicrobial Stewardship Pharmacy Clinical Specialist, Cook Children
  • Cllr. Julie Donoghue – All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases
  • Dr. Grania Brigden – 3P Project Lead,  International Union Against TB and Lung Disease
  • Ms. Debra Palazzi M.D – Associate Professor, Baylor College of Medicine
  • Dr. Lee Morris – Pediatric Infectious Disease, Carolinas Healthcare System
  • Dr. Sandra Arnold – University of Tennessee Health Science Center
  • Caroline Reuter – Pediatric Infectious Disease Fellow, McGaw Medical Center of Northwestern
  • Mª Angeles Muñoz Fernández – Section Head Immunology, Hospital General Universitario Gregorio Marañón
  • Dr. Nipunie Rajapakse – Infectious Diseases Physician, Mayo Clinic
  • Ms. Rosemary Olivero – Section Chief of Pediatric Infectious Diseases, Helen DeVos Children’s Hospital of Spectrum Health
  • Divya Bijlwan – Vice President, Biological E Limited
  • Mr. Upinder Singh – Associate Professor, Stanford University
  • Mr. David Relman – Professor, Stanford University
  • Ms. Tessa Andermann, MD – Infectious Diseases Fellow, Stanford University
  • Dr. Alex Yu – Stanford University
  • Mr. Mikkel Lyndrup – Executive Officer, Statens Serum Institut